Ulisse Biomed S.p.A. (BIT:UBM)

Italy flag Italy · Delayed Price · Currency is EUR
0.7600
-0.0320 (-4.04%)
Mar 31, 2025, 1:42 PM CET
-47.59%
Market Cap 19.39M
Revenue (ttm) 420.92K
Net Income (ttm) -6.97M
Shares Out 24.48M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 24,000
Average Volume 19,250
Open 0.7600
Previous Close 0.7920
Day's Range 0.7600 - 0.7700
52-Week Range 0.7240 - 1.4300
Beta 0.70
RSI 49.49
Earnings Date Mar 28, 2025

About Ulisse Biomed

Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 10
Stock Exchange Borsa Italiana
Ticker Symbol UBM
Full Company Profile

Financial Performance

In 2023, Ulisse Biomed's revenue was 66,208, a decrease of -52.17% compared to the previous year's 138,437. Losses were -4.80 million, 266.8% more than in 2022.

Financial Statements

News

There is no news available yet.